FGF21 and Hepatic steatosis: Elevating serum FGF21 levels through exogenous administration or liver overexpression induces weight loss, enhances energy expenditure, improves glucose metabolism and insulin sensitivity, alleviates hepatic steatosis, promotes lipolysis, induces browning of WAT, and activates BAT function [15–21].